What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Rafael Rosell spends much of his time researching Lung cancer, Internal medicine, Oncology, Chemotherapy and Cancer research.
His research integrates issues of Cancer, Epidermal growth factor receptor, Carcinoma and Surgery in his study of Lung cancer.
Rafael Rosell works mostly in the field of Surgery, limiting it down to topics relating to Clinical trial and, in certain cases, Mediastinoscopy.
Rafael Rosell interconnects Survival analysis, KRAS, Proportional hazards model and Phases of clinical research in the investigation of issues within Oncology.
His studies deal with areas such as Gene expression, DNA methylation, Immunology, DNA repair and Non small cell as well as Cancer research.
His Cisplatin research is multidisciplinary, incorporating elements of Gemcitabine, Urology, Xeroderma pigmentosum and ERCC1.
His most cited work include:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. (3614 citations)
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (3017 citations)
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer (1799 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Oncology, Lung cancer, Cancer research and Chemotherapy.
In most of his Internal medicine studies, his work intersects topics such as Surgery.
His work in Oncology addresses subjects such as Adenocarcinoma, which are connected to disciplines such as Lung and KRAS.
His Lung cancer research focuses on subjects like Epidermal growth factor receptor, which are linked to Mutation.
Rafael Rosell has researched Cancer research in several fields, including Bioinformatics, Tyrosine kinase and Mutant, Gene, DNA repair.
His work carried out in the field of Chemotherapy brings together such families of science as Gastroenterology, Clinical trial and Immunology.
He most often published in these fields:
- Internal medicine (59.15%)
- Oncology (53.71%)
- Lung cancer (47.46%)
What were the highlights of his more recent work (between 2016-2021)?
- Lung cancer (47.46%)
- Internal medicine (59.15%)
- Oncology (53.71%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Lung cancer, Internal medicine, Oncology, Cancer research and Cancer.
His work investigates the relationship between Lung cancer and topics such as Epidermal growth factor receptor that intersect with problems in Tyrosine kinase.
His work on Chemotherapy, Adenocarcinoma, Lung and KRAS as part of general Internal medicine research is often related to In patient, thus linking different fields of science.
His Oncology study frequently intersects with other fields, such as Hazard ratio.
Rafael Rosell combines subjects such as Protein kinase B, Mutant, Receptor tyrosine kinase, Kinase and Osimertinib with his study of Cancer research.
His biological study spans a wide range of topics, including Melanoma and Immunology.
Between 2016 and 2021, his most popular works were:
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer (901 citations)
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. (360 citations)
- Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. (191 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
Lung cancer, Internal medicine, Oncology, Cancer research and Cancer are his primary areas of study.
His research on Lung cancer focuses in particular on Gefitinib.
Rafael Rosell works mostly in the field of Internal medicine, limiting it down to topics relating to Surgery and, in certain cases, T790M, as a part of the same area of interest.
His Oncology study integrates concerns from other disciplines, such as Clinical endpoint and Hazard ratio.
Rafael Rosell interconnects Tyrosine kinase, non-small cell lung cancer, Targeted therapy, Biomarker and Drug resistance in the investigation of issues within Cancer research.
The Cancer study combines topics in areas such as DNA Mutational Analysis, Antibody, Immunology and Tumor cells.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
